Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 337.96 Million EUR | 8.34% |
| 2022 | 311.94 Million EUR | 27.08% |
| 2021 | 245.47 Million EUR | 8.04% |
| 2020 | 227.19 Million EUR | 43.06% |
| 2019 | 158.81 Million EUR | 67.41% |
| 2018 | 94.86 Million EUR | 25.66% |
| 2017 | 75.49 Million EUR | 12.03% |
| 2016 | 67.38 Million EUR | 5.52% |
| 2015 | 63.85 Million EUR | -5.49% |
| 2014 | 67.56 Million EUR | 15.01% |
| 2013 | 58.74 Million EUR | 4.49% |
| 2012 | 56.22 Million EUR | 36.12% |
| 2011 | 41.3 Million EUR | -1.24% |
| 2010 | 41.82 Million EUR | 151.24% |
| 2009 | 16.64 Million EUR | -35.52% |
| 2008 | 25.81 Million EUR | 23.41% |
| 2007 | 20.91 Million EUR | 240.48% |
| 2006 | 6.14 Million EUR | -100.0% |
| 2005 | 1309.87 Billion EUR | 149778.06% |
| 2004 | 873.95 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 337.97 Million EUR | 0.0% |
| 2024 Q2 | 355.48 Million EUR | 5.18% |
| 2023 Q4 | 337.96 Million EUR | -7.58% |
| 2023 FY | 337.96 Million EUR | 8.34% |
| 2023 Q1 | 327.05 Million EUR | 4.85% |
| 2023 Q2 | 351.4 Million EUR | 7.44% |
| 2023 Q3 | 365.67 Million EUR | 4.06% |
| 2022 Q1 | 247.15 Million EUR | 0.68% |
| 2022 FY | 311.94 Million EUR | 27.08% |
| 2022 Q2 | 265.14 Million EUR | 7.28% |
| 2022 Q4 | 311.94 Million EUR | 6.86% |
| 2022 Q3 | 291.93 Million EUR | 10.1% |
| 2021 Q1 | 218.49 Million EUR | -3.83% |
| 2021 Q4 | 245.47 Million EUR | 11.19% |
| 2021 FY | 245.47 Million EUR | 8.04% |
| 2021 Q2 | 198.26 Million EUR | -9.26% |
| 2021 Q3 | 220.76 Million EUR | 11.35% |
| 2020 FY | 227.19 Million EUR | 43.06% |
| 2020 Q4 | 227.19 Million EUR | -4.4% |
| 2020 Q3 | 237.64 Million EUR | 0.77% |
| 2020 Q2 | 235.83 Million EUR | 23.25% |
| 2020 Q1 | 191.34 Million EUR | 20.49% |
| 2019 Q4 | 158.81 Million EUR | 7.78% |
| 2019 Q1 | 108.3 Million EUR | 14.18% |
| 2019 FY | 158.81 Million EUR | 67.41% |
| 2019 Q2 | 121.58 Million EUR | 12.26% |
| 2019 Q3 | 147.35 Million EUR | 21.19% |
| 2018 FY | 94.86 Million EUR | 25.66% |
| 2018 Q3 | 102.55 Million EUR | 12.18% |
| 2018 Q2 | 91.42 Million EUR | 11.78% |
| 2018 Q1 | 81.78 Million EUR | 8.33% |
| 2018 Q4 | 94.86 Million EUR | -7.5% |
| 2017 Q4 | 75.49 Million EUR | 2.26% |
| 2017 FY | 75.49 Million EUR | 12.03% |
| 2017 Q3 | 73.82 Million EUR | 0.61% |
| 2017 Q2 | 73.37 Million EUR | 1.87% |
| 2017 Q1 | 72.03 Million EUR | 6.89% |
| 2016 Q1 | 61.71 Million EUR | -3.35% |
| 2016 Q2 | 61.84 Million EUR | 0.21% |
| 2016 Q3 | 65.61 Million EUR | 6.09% |
| 2016 Q4 | 67.38 Million EUR | 2.71% |
| 2016 FY | 67.38 Million EUR | 5.52% |
| 2015 Q4 | 63.85 Million EUR | -12.62% |
| 2015 Q2 | 69.93 Million EUR | 1.02% |
| 2015 Q3 | 73.07 Million EUR | 4.5% |
| 2015 Q1 | 69.22 Million EUR | 2.46% |
| 2015 FY | 63.85 Million EUR | -5.49% |
| 2014 Q3 | 63.47 Million EUR | -3.92% |
| 2014 Q2 | 66.06 Million EUR | 7.59% |
| 2014 Q4 | 67.56 Million EUR | 6.44% |
| 2014 FY | 67.56 Million EUR | 15.01% |
| 2014 Q1 | 61.4 Million EUR | 4.53% |
| 2013 Q4 | 58.74 Million EUR | -2.71% |
| 2013 Q3 | 60.38 Million EUR | 6.71% |
| 2013 Q2 | 56.58 Million EUR | 9.91% |
| 2013 Q1 | 51.48 Million EUR | -8.43% |
| 2013 FY | 58.74 Million EUR | 4.49% |
| 2012 Q1 | 44.55 Million EUR | 7.87% |
| 2012 Q4 | 56.22 Million EUR | 8.43% |
| 2012 Q3 | 51.85 Million EUR | 5.4% |
| 2012 FY | 56.22 Million EUR | 36.12% |
| 2012 Q2 | 49.19 Million EUR | 10.42% |
| 2011 Q3 | 40.21 Million EUR | 6.11% |
| 2011 FY | 41.3 Million EUR | -1.24% |
| 2011 Q4 | 41.3 Million EUR | 2.71% |
| 2011 Q2 | 37.9 Million EUR | -9.18% |
| 2011 Q1 | 41.73 Million EUR | -0.22% |
| 2010 FY | 41.82 Million EUR | 151.24% |
| 2010 Q4 | 41.82 Million EUR | 0.0% |
| 2009 FY | 16.64 Million EUR | -35.52% |
| 2008 FY | 25.81 Million EUR | 23.41% |
| 2007 FY | 20.91 Million EUR | 240.48% |
| 2006 FY | 6.14 Million EUR | -100.0% |
| 2005 FY | 1309.87 Billion EUR | 149778.06% |
| 2004 FY | 873.95 Million EUR | 0.0% |